CONVERTIBLE DEBT AND EQUITY FINANCINGS |
3. |
CONVERTIBLE DEBT AND EQUITY FINANCINGS |
Between
September 22, 2014, and July 20, 2015, the Company entered into a Note Purchase Agreement (the “Original Note Purchase Agreement”)
in connection with a bridge financing, with nine accredited investors, including lead investor RSJ Private Equity investiční
fond s proměnným základním kapitálem (“RSJ PE”). Pursuant to the Original Note Purchase Agreement,
the Company issued fifteen secured convertible promissory notes (each, a “September 2014 Note”) in the aggregate principal
amount of $2.29 million. Of this amount, RSJ PE purchased a September 2014 Note for $750,000. Michal Votruba, a Director for Life
Sciences for the RSJ/Gradus Fund, subsequently joined our Board on July 30, 2015. The September 2014 Notes were also purchased
by four additional affiliates of the Company (refer to the Note Issuance and Conversion Table below).
The
Original Note Purchase Agreement provided for the issuance and sale of the September 2014 Notes in the aggregate principal amount
of up to $2.5 million, in one or more closings to occur over a six-month period beginning September 22, 2014. The Original Note
Purchase Agreement also provided that the Company and the holders of the September 2014 Notes enter into a registration rights
agreement covering the registration of the resale of the shares of the Common Stock underlying the September 2014 Notes.
On
April 14, 2015, the Company entered into Amendment No. 1 to the Original Note Purchase Agreement with the majority of the noteholders
in principal, dated as of April 14, 2015 (“Amendment No. 1”), pursuant to which: (i) the aggregate principal amount
of notes provided for issuance was increased by $0.5 million to a total of $3.0 million, and (ii) the period to raise the $3.0
million was extended to September 30, 2016. The Company subsequently amended and restated the Original Note Purchase Agreement
solely to update for the changes made pursuant to Amendment No. 1 (such amended and restated agreement, together with the Original
Note Purchase Agreement, the “Note Purchase Agreement”).
On
September 14, 2015, the Company entered into an Omnibus Amendment (the “Omnibus Amendment”) to the Note Purchase Agreement
and the notes purchased and sold pursuant thereto, with the majority of the noteholders to fix the Conversion price of all notes
at $10.00 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock) (the
“Fixed Conversion Price”) (i) automatically, in the event of a qualified financing of not less than $5 million, or
(ii) voluntarily, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached
to the Note Purchase Agreement to reflect the Fixed Conversion Price.
Subsequently
thereto, on September 14, 15 and 24, 2015, the Company entered into a Note Purchase Agreement, as amended by the Omnibus Amendment,
with each of six accredited investors, in connection with a bridge financing. Pursuant to these Note Purchase Agreements, the
Company issued an aggregate principal amount of $710,000 of secured convertible promissory notes (collectively, the “September
2015 Notes,” and together with the September 2014 Notes and all other notes purchased and sold pursuant to the Note Purchase
Agreement, the “Notes”), which amount also represents the gross proceeds to the Company from the September 2015 Notes.
Four of the six September 2015 Notes were purchased by affiliates of the Company, or an entity under such affiliate’s control
(refer to the Note Issuance and Conversion Table below).
Through
December 23, 2015, and prior to further amendments to the Notes, all of the Notes were scheduled to mature on March 21, 2016,
(subject to earlier conversion or prepayment), and earned interest at a rate of 5% per annum with interest payable at maturity.
The Notes could not be prepaid without the prior written consent of the holder of such Notes. The Notes were secured by a security
interest in the Company’s intellectual property, as detailed in a security agreement. Upon a change of control of the Company,
the holder of a Note will have the option to have the Note repaid with a premium equal to 50% of the outstanding principal.
On
December 23, 2015, the Company entered into a Second Amended and Restated Note and Warrant Purchase Agreement (which further amended
and restated the Note Purchase Agreement, as modified by the Omnibus Amendment) (the “Second Amended Note & Warrant
Agreement”) with each of 16 accredited investors, pursuant to which (i) the aggregate principal amount of Notes available
for issuance was increased from $3.0 million to up to $6.0 million, (ii) the maturity date of the Notes outstanding prior to such
amendment was extended from March 21, 2016 to December 31, 2017; (iii) the time during which Notes may be issued was extended
and (iv) certain warrants were issued to holders of both previously issued and Notes issued under the Second Amended Note &
Warrant Agreement.
Pursuant
to the Second Amended Note & Warrant Agreement, on December 23 and December 28, 2015, the Company issued to the two purchasers
thereof, who are both affiliates (refer to the Note Issuance and Conversion Table below) of the Company, (i) an aggregate
principal amount of $1,000,000 of secured convertible promissory notes (each, a “December 2015 Note”), which amount
also represents the gross proceeds to the Company from the December 2015 Notes, and (ii) a warrant to each holder of December
2015 Notes to purchase the Company’s Common Stock, in an amount equal to 100% of the shares underlying their December 2015
Note (each, a “Note Warrant”). Each Note Warrant was exercisable, in whole or in part, during the period beginning
on the date of its issuance, and ending on the earlier of (i) December 31, 2020 and (ii) the date that was forty-five (45) days
following the date on which the daily closing price of shares of the Company’s Common Stock quoted on the OTCQB Venture
Marketplace (or other bulletin board or exchange on which the Company’s Common Stock is traded or listed) exceeded $50.00
for at least ten (10) consecutive trading days. The Note Warrants were subsequently cancelled. For additional details on cancellation
of the Note Warrants, see “—Note Conversion and Warrant Cancellation” below.
Also
on December 23, 2015, in consideration for the agreement to extend the maturity date of the Notes, the Company issued to holders
of all Notes outstanding prior to the date of the Second Amended Note & Warrant Agreement, warrants to purchase an aggregate
of 300,000 shares of Common Stock (the “Extension Warrants”, together with the Note Warrants, the “Warrants”).
All Warrants had identical terms. Each such holder was issued an Extension Warrant to purchase Common Stock in an amount equal
to 100% of the shares underlying each such holder’s previously outstanding Notes. Extension Warrants were issued to affiliates
(refer to the Note Issuance and Conversion Table below). All Note Warrants and Extension Warrants were subsequently cancelled
upon conversion of the Notes. or additional details on cancellation of the Warrants, see “—Note Conversion and
Warrant Cancellation” below.
Between
February 23, 2016 and June 30, 2016, the Company issued to seven accredited investor purchasers thereof (i) an aggregate principal
amount of $1,100,000 in eight separate Notes and (ii) a warrant to each holder of such Notes to purchase the Company’s Common
Stock, in an amount equal to 100% of the shares underlying their respective Note (each, also a “Note Warrant”). A
total of 110,000 shares of Common Stock in the aggregate were underlying these Note Warrants. Five of the purchasers were affiliates
of the Company (refer to the Note Issuance and Conversion Table below). The Note Warrants were subsequently cancelled.
For additional details on cancellation of the Note Warrants, see “Note Conversion and Warrant Cancellation”
below.
On
August 15, 2016, the Company entered into an Amendment No. 1 to the Second Amended Note and Warrant Agreement with the investors
party thereto to extend the time during which the Notes and the Warrants could be issued under the Second Amended Note and Warrant
Agreement from August 11, 2016 to September 1, 2016.
On
September 19, 2016, the Company entered into a Second Omnibus Amendment (the “Second Omnibus Amendment”), with a majority
of over 80% of the noteholders, thereby amending: (i) the Notes, (ii) the Second Amended Note and Warrant Agreement, as amended
and (iii) the Warrants. Pursuant to the Second Omnibus Amendment, the Company had the option, exercisable at any time after September
1, 2016, to mandatorily convert all Notes into shares of the Company’s common stock at $5.00 per share (the “Mandatory
Conversion”).
Note
Conversion and Warrant Cancellation
On
September 19, 2016, pursuant to the Second Omnibus Amendment, the Company exercised the Mandatory Conversion and, on September
21, 2016, (i) converted the entire outstanding principal balance of $6,000,000, plus accrued interest of $317,000 on all of the
Notes into 1,263,406 shares of the Company’s common stock at a conversion price of $5.00 per share and (ii) cancelled all
Warrants (refer to the Note Issuance and Conversion Table below).
The
below table sets forth details regarding the shares issued to certain related parties upon the Company’s exercise of the
Mandatory Conversion:
Note
Issuance and Conversion Table:
Note Holder |
|
|
|
|
Principal Amount |
|
|
2016
Discount |
|
|
Carrying
Value September 30, 2016 |
|
|
Accrued Interest
at Conversion |
|
|
Shares issued on
Conversion |
|
Original
Note Purchase Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note
Date Range Sept 22, 2014 to July 20, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RSJ Private
Equity |
|
|
(1) |
|
|
$ |
750,000 |
|
|
$ |
21,300 |
|
|
$ |
728,700 |
|
|
$ |
76,200 |
|
|
|
165,246 |
|
John Pappajohn |
|
|
(2) |
|
|
|
200,000 |
|
|
|
8,100 |
|
|
|
191,900 |
|
|
|
20,400 |
|
|
|
44,089 |
|
John Pappajohn |
|
|
(5) |
|
|
|
200,000 |
|
|
|
3,000 |
|
|
|
197,000 |
|
|
|
14,200 |
|
|
|
42,820 |
|
Tierney Family Trust |
|
|
(3) |
|
|
|
540,000 |
|
|
|
16,000 |
|
|
|
524,000 |
|
|
|
46,000 |
|
|
|
117,199 |
|
Follman Family Trust |
|
|
(4) |
|
|
|
100,000 |
|
|
|
3,000 |
|
|
|
97,000 |
|
|
|
7,700 |
|
|
|
21,538 |
|
Oman Ventures |
|
|
(6) |
|
|
|
200,000 |
|
|
|
8,100 |
|
|
|
191,900 |
|
|
|
20,400 |
|
|
|
44,089 |
|
4
Accredited Investors |
|
|
|
|
|
|
300,000 |
|
|
|
9,100 |
|
|
|
290,900 |
|
|
|
30,600 |
|
|
|
66,112 |
|
Subtotal
for First Round |
|
|
|
|
|
$ |
2,290,000 |
|
|
$ |
68,600 |
|
|
$ |
2,221,400 |
|
|
|
|
|
|
|
|
|
Omnibus
Amendment Sept 14, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note
Date Range Sept 14, 2015 to September 24, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RSJ Private Equity |
|
|
(1) |
|
|
$ |
350,000 |
|
|
$ |
85,400 |
|
|
$ |
264,600 |
|
|
|
17,300 |
|
|
|
73,462 |
|
Robin Smith |
|
|
(2) |
|
|
|
60,000 |
|
|
|
7,100 |
|
|
|
52,900 |
|
|
|
3,100 |
|
|
|
12,611 |
|
John Pappajohn |
|
|
(2) |
|
|
|
100,000 |
|
|
|
24,400 |
|
|
|
75,600 |
|
|
|
5,100 |
|
|
|
21,015 |
|
Follman Family Trust |
|
|
(4) |
|
|
|
150,000 |
|
|
|
36,500 |
|
|
|
113,500 |
|
|
|
7,600 |
|
|
|
31,522 |
|
2
Accredited Investors |
|
|
|
|
|
|
50,000 |
|
|
|
12,200 |
|
|
|
37,800 |
|
|
|
2,500 |
|
|
|
10,508 |
|
Subtotal
for Second Round |
|
|
|
|
|
$ |
710,000 |
|
|
$ |
165,600 |
|
|
$ |
544,400 |
|
|
|
|
|
|
|
|
|
Balances
at September 30, 2015 |
|
|
|
|
|
$ |
3,000,000 |
|
|
$ |
234,200 |
|
|
$ |
2,765,800 |
|
|
|
|
|
|
|
|
|
Second Amended
Note December 23 & 28, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RSJ Private Equity |
|
|
(1) |
|
|
$ |
750,000 |
|
|
|
|
|
|
|
|
|
|
|
27,300 |
|
|
|
155,465 |
|
John
Pappajohn |
|
|
(2) |
|
|
|
250,000 |
|
|
|
|
|
|
|
|
|
|
|
9,300 |
|
|
|
51,856 |
|
Subtotal
for Third Round |
|
|
|
|
|
$ |
1,000,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note Date Range
Feb 23, 2016 to August 16, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RSJ Private Equity |
|
|
(1) |
|
|
$ |
250,000 |
|
|
|
|
|
|
|
|
|
|
|
1,400 |
|
|
|
50,281 |
|
Robin Smith |
|
|
(2) |
|
|
|
40,000 |
|
|
|
|
|
|
|
|
|
|
|
800 |
|
|
|
8,165 |
|
John Pappajohn |
|
|
(2) |
|
|
|
850,000 |
|
|
|
|
|
|
|
|
|
|
|
14,000 |
|
|
|
172,802 |
|
Tierney Family Trust |
|
|
(3) |
|
|
|
100,000 |
|
|
|
|
|
|
|
|
|
|
|
600 |
|
|
|
20,129 |
|
Follman Family Trust |
|
|
(4) |
|
|
|
300,000 |
|
|
|
|
|
|
|
|
|
|
|
5,100 |
|
|
|
61,014 |
|
Carpenter, George &
Jill |
|
|
(7) |
|
|
|
100,000 |
|
|
|
|
|
|
|
|
|
|
|
1,300 |
|
|
|
20,254 |
|
Harris, Geoffrey |
|
|
(2) |
|
|
|
10,000 |
|
|
|
|
|
|
|
|
|
|
|
300 |
|
|
|
2,058 |
|
2 Accredited Investors |
|
|
|
|
|
|
300,000 |
|
|
|
|
|
|
|
|
|
|
|
5,600 |
|
|
|
61,124 |
|
Brandt
Ventures |
|
|
(8) |
|
|
|
50,000 |
|
|
|
|
|
|
|
|
|
|
|
200 |
|
|
|
10,047 |
|
Subtotal
for Final Round |
|
|
|
|
|
$ |
2,000,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances
Converted September 19, 2016 |
|
|
|
|
|
$ |
6,000,000 |
|
|
|
|
|
|
|
|
|
|
$ |
317,000 |
|
|
|
1,263,406 |
|
|
(1) |
RSJ PE is a greater
than 5% shareholder. Michal Votruba, a Director for Life Sciences for the RSJ/Gradus Fund, subsequently joined our Board on
July 30, 2015. |
|
(4) |
Robert Follman is a trustee of the Follman Family
Trust and is a member of the Board. Mr. Follman resigned from the board on July 14, 2017. |
|
(5) |
John Pappajohn is a member of the Board. He
purchased $200,000 of Notes, which on September 6, 2015, were assigned to four accredited investors. Approximately $10,400
of interest was attributable to such transferred Notes, resulting in an aggregate of 42,084 shares being issued upon the Mandatory
Conversion of such transferred Notes. |
|
(6) |
Mark & Jill Oman are the beneficial owners
of Oman Ventures and were greater than 5% shareholders of the Company. |
|
(8) |
Brandt Ventures was issued this note as part
of the Company’s settlement of its litigation with Leonard Brandt and Brandt Ventures (refer to Note 9. Commitments
and Contingent Liabilities). |
Warrants
In
July 2017, the Company completed an underwritten public offering of its Common Stock and warrants, raising gross proceeds of
approximately $8.79 million. In the offering, the Company sold 1,675,000 shares of Common Stock and accompanying warrants to
purchase up to 1,675,000 shares of Common Stock (the “Warrants”), at a combined public offering price of $5.25
per share and accompanying Warrant, for a total offering size of $8,793,750. The Warrants were immediately exercisable for
one share of Common Stock at an exercise price of $5.25 per share, subject to adjustments, and will expire five years after
the issuance date. Direct costs associated with the offering amount to $1,313,800 plus the warrants
issued to the under writers as discussed below.
The
public offering warrant has an exercise price of $5.25 and expires on July 19, 2022. We estimated the fair value of the public
offering warrant at issuance date to be $10,802,728 using the Black-Scholes option valuation model with the following assumptions:
market price of the stock of $6.55 per share, time to maturity of 5 years, volatility of 211.6%, zero expected dividend rate and
risk-free rate of 1.89%. These warrants qualify for equity treatment. The allocation of the fair value of these warrants was included
in additional paid-in capital on the consolidated balance sheet.
As
part of the underwritten public offering on July 19, 2017, the Company issued 134,000 common stock warrants to the underwriters
as part of the services performed by them in connection with the underwritten public offering. The underwriter warrant has an
exercise price of $6.04 and expires on July 19, 2022. We estimated the fair value of the underwriter warrant at issuance date
to be $863,225 using the Black-Scholes option valuation model with the following assumptions: market price of the stock of $6.55
per share, time to maturity of 5 years, volatility of 211.6%, zero expected dividend rate and risk-free rate of 1.89%. These warrants
qualify for equity treatment. The allocation of the fair value of these warrants was included in additional paid-in capital on
the consolidated balance sheet.
On
August 23, 2017, the Company issued 213,800 common stock warrants to underwriters as part of the overallotment attributed
to the July 2017 underwritten public offering. Gross proceeds amounted to $2,100. The overallotment warrant has an exercise
price of $5.25 and expires on July 19, 2022. We estimated the fair value of the overallotment warrant at issuance date to
be $880,710 using the Black-Scholes option valuation model with the following assumptions: market price of the stock of
$4.20 per share, time to maturity of 5 years, volatility of 211.6%, zero expected dividend rate and risk-free rate of 1.89%.
These warrants qualify for equity treatment. The allocation of the fair value of these warrants was included in additional
paid-in capital on the consolidated balance sheet.
Stock
Dividend Warrants
On
July 13, 2017, the Company declared a special dividend of warrants to purchase shares of the Company’s common stock to record
holders of Common Stock as of such date. Warrants to purchase 2,539,061 shares of Common Stock were distributed pro rata to all
holders of common stock on the record date. These warrants will be exercisable (in accordance with their terms) to purchase one
share of common stock, at an exercise price of $5.25 per share. The warrants will become exercisable commencing not less than
12 months following their July 27, 2017 distribution date and will expire five years thereafter.
The
dividend warrant has an exercise price of $5.25 and expires on July 26, 2022. We estimated the fair value of the dividend warrant
at issuance date to be $16,375,394 using the Black-Scholes option valuation model with the following assumptions: market price
of the stock of $6.55 per share, time to maturity of 5 years, volatility of 211.6%, zero expected dividend rate and risk-free
rate of 1.89%. These warrants qualify for equity treatment. The allocation of the fair value of these warrants was included in
additional paid-in capital on the consolidated balance sheet. The Company also recognized a dividend related to the dividend warrants
as every shareholder was entitled to receive one warrant for every share of common stock for no consideration given. Accordingly,
the Company recognized a $16,375,394 dividend at closing.
|